Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Jan;51(1):77–84. doi: 10.1038/bjc.1985.11

The effect of systemic hyperthermia on melphalan pharmacokinetics in mice.

D J Honess, J Donaldson, P Workman, N M Bleehen
PMCID: PMC1976822  PMID: 3966973

Abstract

The effect of 45 min systemic heating at 41 degrees C on plasma and RIF-1 tumour pharmacokinetics of intraperitoneally administered melphalan (MEL) was studied in C3H mice. This heat dose causes greater potentiation of MEL in tumour than in marrow cells, resulting in a therapeutic gain for the combined therapy (Honess & Bleehen, 1985). MEL (7.5 mg kg-1) was administered at the start of heating and concentrations assayed from 20-90 min by high-performance liquid chromatography (HPLC). With or without heat peak concentrations were achieved by 20 min and were 3 to 4 micrograms ml-1 in plasma and 1-3 micrograms g-1 in tumour. Higher MEL concentrations in both plasma and tumour were found in heated animals at times after 20 min from injection, but the effect was greater in plasma (2.5-4 fold) than in tumour (1.5-2 fold) where differences were not always significant. At 40 min after a dose of 7.5 mg kg-1, plasma and tumour concentrations in heated animals were equivalent to those after 12.5 mg kg-1 and 8.5 mg kg-1, respectively, without heating. Tumour/plasma ratios were usually lower in heated than in unheated animals where they often exceeded 100%. The apparent plasma elimination half-life (t1/2) was 17.5-25 min in unheated and 24-44 min in heated animals. The area under the curve (AUC) was increased by a factor of 1.2-1.5 in heated animals, at least partly due to a decrease in volume of distribution. The heat induced increase in MEL exposure may be involved in the enhanced response to the drug, but does not appear to explain the therapeutic gain compaired to MEL alone.

Full text

PDF
77

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Peng Y. M., Chen H. S., Moon T. E., Cetas T. C., Hoeschele J. D. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Cancer Inst. 1980 Aug;65(2):455–461. [PubMed] [Google Scholar]
  2. Begleiter A., Froese E. K., Goldenberg G. J. A comparison of melphalan transport in human breast cancer cells and lymphocytes in vitro. Cancer Lett. 1980 Sep;10(3):243–251. doi: 10.1016/0304-3835(80)90077-4. [DOI] [PubMed] [Google Scholar]
  3. Begleiter A., Lam H. Y., Grover J., Froese E., Goldenberg G. J. Evidence for active transport of melphalan by two amino acid carriers in L5178Y lymphoblasts in vitro. Cancer Res. 1979 Feb;39(2 Pt 1):353–359. [PubMed] [Google Scholar]
  4. Ehrsson H., Lönroth U. Degradation of melphalan in aqueous solutions--influence of human albumin binding. J Pharm Sci. 1982 Jul;71(7):826–827. doi: 10.1002/jps.2600710729. [DOI] [PubMed] [Google Scholar]
  5. Evans T. L., Chang S. Y., Alberts D. S., Sipes I. G., Brendel K. In vitro degradation of L-phenylalanine mustard (L-PAM). Cancer Chemother Pharmacol. 1982;8(2):175–178. doi: 10.1007/BF00255479. [DOI] [PubMed] [Google Scholar]
  6. Furner R. L., Brown R. K. L-phenylalanine mustard (L-PAM): the first 25 years. Cancer Treat Rep. 1980 Apr-May;64(4-5):559–574. [PubMed] [Google Scholar]
  7. Furner R. L., Mellett L. B., Brown R. K., Duncan G. A method for the measurement of L-phenylalanine mustard in the mouse and dog by high-pressure liquid chromatography. Drug Metab Dispos. 1976 Nov-Dec;4(6):577–583. [PubMed] [Google Scholar]
  8. Hinchliffe M., McNally N. J., Stratford M. R. The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse. Br J Cancer. 1983 Sep;48(3):375–383. doi: 10.1038/bjc.1983.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Honess D. J., Bleehen N. M. Sensitivity of normal mouse marrow and RIF-1 tumour to hyperthermia combined with cyclophosphamide or BCNU: a lack of therapeutic gain. Br J Cancer. 1982 Aug;46(2):236–248. doi: 10.1038/bjc.1982.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Honess D. J., Bleehen N. M. Thermochemotherapy with cis-platinum, CCNU, BCNU, chlorambucil and melphalan on murine marrow and two tumours: therapeutic gain for melphalan only. Br J Radiol. 1985 Jan;58(685):63–72. doi: 10.1259/0007-1285-58-685-63. [DOI] [PubMed] [Google Scholar]
  11. Honess D. J., Workman P., Morgan J. E., Bleehen N. M. Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetized mouse. Br J Cancer. 1980 Apr;41(4):529–540. doi: 10.1038/bjc.1980.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Longo F. W., Tomashefsky P., Rivin B. D., Tannenbaum M. Interaction of ultrasonic hyperthermia with two alkylating agents in a murine bladder tumor. Cancer Res. 1983 Jul;43(7):3231–3235. [PubMed] [Google Scholar]
  13. Magin R. L., Cysyk R. L., Litterst C. L. Distribution of adriamycin in mice under conditions of local hyperthermia which improve systemic drug therapy. Cancer Treat Rep. 1980 Feb-Mar;64(2-3):203–210. [PubMed] [Google Scholar]
  14. Mimnaugh E. G., Waring R. W., Sikic B. I., Magin R. L., Drew R., Litterst C. L., Gram T. E., Guarino A. M. Effect of whole-body hyperthermia on the disposition and metabolism of adriamycin in rabbits. Cancer Res. 1978 May;38(5):1420–1425. [PubMed] [Google Scholar]
  15. Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
  16. Vistica D. T. Cytotoxicity as an indicator for transport mechanism: evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell. Biochim Biophys Acta. 1979 Jan 19;550(2):309–317. doi: 10.1016/0005-2736(79)90217-7. [DOI] [PubMed] [Google Scholar]
  17. Workman P., Double J. A., Wilman D. E. Enzyme activated anti-tumour agents--III. Hydrolysis of conjugates of p-hydroxyaniline mustard in aqueous solution. Biochem Pharmacol. 1976 Nov 1;25(21):2347–2350. doi: 10.1016/0006-2952(76)90026-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES